Regular articleCGP 36742: The first orally active GABAB blocker improves the cognitive performance of mice, rats, and rhesus monkeys
References (33)
- et al.
Increased acetylcholine and quisqualatate responsiveness following blockade of GABAB receptors
European Journal of Pharmacology
(1992) - et al.
Muscimol binding in rat brain: Associations with synaptic GABA receptors
Brain Research
(1978) GABAB receptors and their significance in mammalian pharmacology
Trends in Pharmacological Science
(1989)- et al.
A comparison of the effects of fornix transsection and sulcus principalis ablation upon spatial learning in monkeys
Behavioural Brain Research
(1989) - et al.
The mnemon and its juices: Neuromodulation of memory processes
Behavioral and Neural Biology
(1983) - et al.
CGP 35348: A centrally active blocker of GABAB receptors
European Journal of Pharmacology
(1990) - et al.
The cholinergic hypothesis: A historical overview, current perspective, and future directions
- et al.
GABAB antagonists: Potential new drugs
Pharmacology Communications
(1992) - et al.
Biochemistry, electrophysiology and pharmacology of a new GABAB antagonist: CGP 35348
- et al.
Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor
Nature
(1980)
GABAergic modulation of memory
Post-training systemic and intraamygdala administration of the GABAB agonist Baclofen impairs retention
Behavioral and Neural Biology
GABAB autoreceptors regulate the induction of LTP
Nature
A physiological role for GABAB receptors in the central nervous system
Nature
Place memory and scene memory: Effects of fornix transsections in the monkey
Experimental Brain Research
A generalized Wilcoxon test for comparing arbitrarily single censored samples
Biometrika
Cited by (110)
How do stupendous cannabinoids modulate memory processing via affecting neurotransmitter systems?
2021, Neuroscience and Biobehavioral ReviewsSynopsis of recent synthetic methods and biological applications of phosphinic acid derivatives
2020, TetrahedronCitation Excerpt :Other important attributes of these scaffolds would be drug applications for diverse therapeutic implementation. Many of them are currently in clinical research and development, summarizing the most important developments of drug design based on phosphinic acids (Fig. 5) [237–304]. The literature survey presented herein clearly demonstrate that phosphinic acid derivatives are readily obtainable and a valuable building block in organic synthesis.
Role of CA1 GABA<inf>A</inf> and GABA<inf>B</inf> receptors on learning deficit induced by D-AP5 in passive avoidance step-through task
2018, Brain ResearchCitation Excerpt :Given that baclofen can affect both acquisition and consolidation of memory in Morris water maze task, it would be expected that GABABR antagonists also produce some effect. Administration of GABABR antagonists to investigate memory acquisition in passive avoidance tasks induced a positive effect only in studies that an antagonist was administered repeatedly and systemically prior to the training (Yu et al., 1997), or specifically when the drug was administered orally (Mondadori et al., 1993). No effect was observed When the drug was not administered systemically (Zarrindast et al., 2008) or was administered only once (Dubrovina and Zinov'ev, 2008).
The role of CA3 GABA<inf>B</inf> receptors on anxiolytic-like behaviors and avoidance memory deficit induced by D-AP5 with respect to Ca<sup>2 +</sup> ions
2017, Progress in Neuro-Psychopharmacology and Biological PsychiatryCitation Excerpt :Previous researchers have proved the involvement of the NMDA receptors (NMDARs) (Guimaraes et al., 1991) and GABA receptors (Millan, 2003), including GABAB receptors (GABABRs) (Helm et al., 2005; Sunyer et al., 2007) in the improvement of anxiety and memory states (Bowery et al., 2002, Joanna M Wierońska, 2011, Staubli et al., 1999). There are reports of the cognitive function enhancement in several species by GABABR antagonists in different functional tests (Mondadori et al., 1993) and it has been proposed that GABABR antagonism may enhance cognition by elevating the neural activity in the hippocampus (Cryan and Slattery, 2010). However, we still need a better understanding of the interaction between these two systems to be able to provide novel ways of treatment with fewer side effects.
Possible involvement of the CA1 GABAergic system on harmaline induced memory consolidation deficit
2017, Brain Research BulletinRole of GABA<inf>B</inf> receptors in learning and memory and neurological disorders
2016, Neuroscience and Biobehavioral ReviewsCitation Excerpt :Given that baclofen can affect both acquisition and consolidation of this task, it would be expected that GABAB receptor antagonists also produce some effect. In the instances an antagonist is used to investigate task acquisition, a positive effect is found only in studies that administered an antagonist repeatedly and systemically prior to training (Getova and Dimitrova, 2007; Yu et al., 1997), or specifically when the drug is administered orally (Mondadori et al., 1993). When not administered systemically (Zarrindast et al., 2008) or only administered once (Dubrovina and Zinov'ev, 2008; Zarrindast et al., 1998), no effect is observed.
- 1
The results were presented at the Second International GABAB Meeting in Interlaken, Switzerland, October 21–23, 1992.